CHF 967.0 million
CHF 378.4 million
CHF 333.0 million
CHF 324.7 million
1,825 (1,752 full-time equivalents)
Vifor Pharma achieved strong growth with Ferinject® in all regions, including the important US market where Injectafer® has become the market-leading high dose product and continues to build adoption in the critical haematology segment.
number of countries in which Ferinject® was registred in 2015
The roll-out of the new phosphate binder Velphoro® in the USA and major European markets continued to drive the expansion in the broader nephrology market.
Vifor Pharma signed an exclusive licensing agreement for the commercialisation of Roche’s drug Mircera® in the USA and Puerto Rico. And VFMCRP entered into an exclusive partnership with the US company Relypsa to commercialise the potassium binder Patiromer FOS in all markets outside the USA and Japan.
In the immunostimulant product range, progress was made in life cycle management.
Preparations continued to prepare the organisation for its future as a stand-alone business, making progress in terms of structure, governance and processes.
The top priority is to retain the global leadership position and assure expansion in the iron deficiency market. Emphasis is on further expansion of Ferinject®/Injectafer® in existing markets, in particular the USA. Ferinject®/Injectafer® growth will be supported by launches in additional countries in 2016.
Vifor Pharma will also back the common company VFMCRP in extending its position as leading player in nephrology. Core activities include the successful continuation of the Velphoro® launch programme and pre-launch activities for Patiromer FOS.